Replies to post #778353 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The absence of a separately labeled expense line for the UK Specials program does not mean the program is negligible — it reflects how costs are categorized under GAAP and SEC reporting standards for a pre-commercial biotech.

We know from the 2024 10-K that Specials-related costs are reported under R&D. This is confirmed directly:

“The increase in R&D expenses for 2024 as compared to 2023 was primarily due to…
• $0.8 million for manufacturing cost increases in the Specials-Compassionate Treatment program…”

— NWBO 2024 10-K, page F-36

That $0.8 million reflects the year-over-year increase, not the total. The total cost of manufacturing is addressed elsewhere:

“During the year ended December 31, 2024, the Company paid Advent approximately $19.0 million in connection with the manufacture of DCVax-L for clinical trial and Specials use.”

— NWBO 2024 10-K, page F-30

Because DCVax-L is a personalized, autologous cell therapy, each dose must be custom-manufactured from an individual patient’s tumor lysate and dendritic cells under full GMP conditions. That type of manufacturing does not scale like traditional drugs — each batch is labor-intensive and highly regulated. The manufacturing infrastructure must be maintained at full operational readiness (cleanrooms, QA/QC, personnel, documentation) whether treating 10 patients or 100.

So yes, NWBO is paying Advent significant sums — but this is entirely normal and expected for a company producing a personalized, unlicensed biologic under regulatory frameworks like the UK’s Specials program. It reflects the high fixed costs of maintaining manufacturing readiness and compliance — not overpayment or inefficiency.

As for revenue, NWBO reported $1.382 million in 2024 from the Specials program. That may not reflect the full extent of treatment activity because, under GAAP, revenue for unlicensed biologics can only be recognized when payment is received and collection is assured. This deferral is standard in early access programs across the industry and results in a timing lag between treatment and reported income.

Additionally, UK-based patients have publicly sought funds — often between $50,000 and $150,000 — to access DCVax-L under the Specials framework. That clearly undermines the idea that NWBO is delivering therapy at no cost or without economic consequence.

In short, the Specials program has real operational and financial impact. It’s reported within standard categories like R&D and subject to the regulatory and accounting norms that apply to therapies in pre-commercial use. The lack of a dedicated line item reflects the structure of the program — not the absence of activity.

[Slave1]

Jerry,
The $0.8M figure is not in dispute. It’s a year-over-year increase related to Specials manufacturing. But that’s not the full picture, and you know that.

What I’m struggling with is why the broader disclosure ($19M to Advent, GMP-based Specials infrastructure, QP-released patient-specific therapy) keeps getting narrowed down to a single delta, as if that’s the whole story.

You’re presenting one tile and calling it the mosaic.

The regulatory structure behind Specials and IFR is fully visible, MHRA-authorized, traceable, and tightly governed. And if the goal is clarity, we can walk through all of it. But if the goal is constant zoom-in on partial context, while ignoring the operational and legal reality, then I have to ask:

What’s the actual intent here?

Because it reads less like analysis, and more like someone trying to hold the signal underwater.

Happy to clarify if needed. But let’s not pretend this is about just one number. It hasn’t been for a long time.